Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Resistance and cross-resistance of the IgM immunocytoma in the LOU/M Wsl rat for cisplatin, carboplatin, and iproplatin

  • 20 Accesses

  • 3 Citations

Summary

We investigated the antitumor activity of cis-diammine[1,1-cyclobutanedicarboxylato]platimum(II) (CBDCA, JM8) and cis-dichloro-trans-dihydroxybis(isopropylammine)platinum(IV) (CHIP, JM9) for the cis-DDP-sensitive and-resistant IgM immunocytoma in the LOU/M Wsl rat. The optimal dose for the antitumor effect of cis-diamminedichloroplatinum (cis-DDP) in this tumor model is 1 mg/kg body weight. In order to determine the dose range for antitumor activity of JM8 and JM9, tumorbearing rats were treated i. p. (twice weekly) with 2, 4, 8, 16, or 32 mg/kg JM8 or with 2, 4, or 8 mg/kg JM9. The maximal antitumor activity of JM8 was found at a dose of 4–8 mg/kg and that of JM9, at 4 mg/kg. Doses of 16 or 32 mg/kg JM8 did not increase the antitumor activity. Recurrence of tumors was observed in JM8- and JM9-treated rats. It was demonstrated that these relapses during treatment with JM8 or JM9 involved tumor cell populations almost completely resistant against therapy with the respective durgs. The growth of cis-DDP-resistant tumors was not influenced by the analog JM9 (4 and 8 mg/kg). Only a high dose of JM8 (32 mg/kg) caused growth retardation of the cis-DDP-resistant IgM subline. The JM8-resistant tumor was resistant to treatment with cis-DDP (1 and 2 mg/kg). The JM9-resistant tumor was also resistant to this treatment (1 mg/kg); however, at a dose of 2 mg/kg cis-DDP, growth retardation of the tumor occurred. We conclude that cis-DDP, JM8, and JM9 induce resistance in the IgM immunocytoma tumor system; tumors resistant for cis-DDP were not sensitive to the treatment with JM8 or JM9. Although JM9 reacts in vitro distinctly differently with DNA than cis-DDP and JM8, no differences were found in the induction of Pt resistance. In this study tumor cells were readily made resistant, which allows us to study in more detail the induction of (cross-) resistance by cis-DDP, JM8, and JM9.

This is a preview of subscription content, log in to check access.

Abbreviations

Cisplatin or cis-DDP:

cis-diamminedichloroplatinum(II)

CBDCA, carboplatin, or JM8:

cis-diammine[1,1-cyclobutanedicarboxylato]platinum(II)

CHIP, iproplatin, or JM9:

cis-dichloro-trans-dihydroxybis(isopropylammine) platinum(IV)

TNO-6:

cis-1,1-diaminomethylcyclohexaneplatinum(II)sulfate

IgM/cis-DDP:

IgM immunocytoma resistant to treatment with cis-DDP

IgM/JM8:

IgM immunocytoma resistant to treatment with JM8

IgM/JM9:

IgM immunocytoma resistant to treatment with JM9

References

  1. 1.

    Bakka A, Endresen L, Johnsen ABS, Edminson PD, Rugstad HE (1981) Resistance against cis-dichlorodiammineplatinum in cultured cells with a high content of metallothionein. Toxicol Appl Pharmacol 61:215–226

  2. 2.

    Bazin H, Deckers C, Beckers A, Heremans JF (1972) Transplantable immunoglobulin secreting tumors in rats: general features of LOU/Wsl strain rat immunocytoma and their monoclonal proteins. Int J Cancer 10:568–580

  3. 3.

    Bradner WT, Rose WC, Huftalen JB (1980) Antitumor activity of platinum analogs. In: Prestayko AW, Crooke ST, Carter SK (eds) Cisplatin: Current status and new developments. Academic Press, New York, pp 171–182

  4. 4.

    Bramwell VHC, Crowther D, O'Malley S, Swindell R, Johnson R, Cooper EH, Thatcher N, Howell A (1985) Activity of JM9 in advanced ovarian cancer: A phase I–II trial. Cancer Treat Rep 69:409–416

  5. 5.

    Burchenal JH, Kalaher K, O'Toole T, Chisholm J (1977) Lack of cross-resistance between certain platinum coordination compounds in mouse leukemia. Cancer Res 37:3455–3457

  6. 6.

    Burchenal JH, Kalaher K, Dew K, Lokys L, Gale G (1978) Studies of cross-resistance, synergistic combinations and blocking of activity of platinum derivatives. Biochimie 60:961–965

  7. 7.

    Burchenal JH, Kalaher K, Dew K, Lokys L (1979) Rationale for development of platinum analogs. Cancer Treat Rep 63:1493–1498

  8. 8.

    Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ, Harrap KR (1982) Early clinical studies with cis-diammine 1-1-cyclobutane diacarboxylate platinum II. Cancer Chemother Pharmacol 9:140–147

  9. 9.

    Connors TA, Cleare MJ, Harrap KR (1979) Structure-activity relationships of the antitumor platinum coordination complexes. Cancer Treat Rep 63:1499–1502

  10. 10.

    Eastman A (1983) Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum (II) and cisdichloro(ethylenediammine)platinum(II). Biochemistry 22:3927–3933

  11. 11.

    Evans BD, Raju KS, Calvert AH, Harland SJ, Wiltshaw E (1983) Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma. Cancer Treat Rep 67:997–1000

  12. 12.

    Fichtinger-Schepman AMJ, Veer van der JL, Hertog den JHJ, Lohman PHM, Reedijk J (1985) Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification and quantitation. Biochemistry 24:702–713

  13. 13.

    Harrap KR, Jones M, Wilkinson CR, Clink HMcD, Sparrow S, Mitchley BCV, Clarke S, Veasey A (1980) Anti-tumor, toxic and biochemical properties of cisplatin and eight other platinum complexes. In: Prestayko AW, Crooke ST, Carter SK (eds) Cisplatin: Current status and new developments. Academic Press, New York, pp 193–212

  14. 14.

    Hromas RA, North JA, Burns CP (1986) Cis-platinum uptake in L1210 leukemia cells resistant and sensitive to the drug. Proc Am Assoc Cancer Res 27:263

  15. 15.

    Jong de WH, Steerenberg PA, Bulten EJ, Verbeek F, Kruizinga W, Ruitenberg EJ (1983) Antitumor activity, induction of cross-resistance, and nephrotoxicity of a new platinum analogue, cis-1,1-diaminomethylcyclohexaneplatinum(II) sulfate, and of cis-diamminedichloroplatinum(II) in an immunocytoma model in the LOU/M rat. Cancer Res 43:4927–4934

  16. 16.

    Knox RJ, Friedlos F, Lydall DA, Roberts JJ (1986) Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine (1,1 cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 46:1972–1979

  17. 17.

    Lee FH, Canetta R, Issell BF, Lenaz L (1983) New platinum complexes in clinical trials. Cancer Treat Rev 10:39–51

  18. 18.

    Lelieveld P, Vijgh van der WJF, Veldhuizen RW, Velzen van D, Putten van LM, Atassi G, Dangny A (1984) Preclinical studies on toxicity anti-tumor activity and pharmacokinetics of cisplatin and three recently developed derivatives. Eur J Cancer Clin Oncol 20:1087–1104

  19. 19.

    Macquet JP, Butour JL, Razaka H, Salles B, Vieussens C, Wright M (1984) Is DNA the real target of the antitumor platinum compounds? In: Hacker MP, Douple EB, Krakoff IH (eds) Platinum coordination complexes in cancer chemotherapy. Martinus Nijhoff, Boston, pp 27–38

  20. 20.

    McMillan TJ, Stephens TC, Steel GG (1985) Development of drug resistance in a murine mammary tumor. Br J Cancer 1:823–832

  21. 21.

    Micetich KC, Barnes D, Erickson LC (1985) A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum(II) and cis-diamminedichloroplatinum(II) on L1210 cells. Cancer Res 45:4043–4047

  22. 22.

    Mong S, Eubanks DC, Prestayko AW, Crooke ST (1982) Characterization of in vitro deoxyribonucleic acid breakage and cross-linking induced by bis (iso propylamine)-transdihydroxy-cis-dichloroplatinum(IV). Biochemistry 21:3174–3180

  23. 23.

    Pascoe JM, Roberts JJ (1974) Interactions between mammalian cell DNA and inorganic platinum compounds: I. DNA interstrand cross-linking and cytotoxic properties of platinum (II) compounds. Biochem Pharmacol 23:1345–1357

  24. 24.

    Peckham MJ, Horwich A, Hendry WF (1985) Advanced seminoma: Treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8). Br J Cancer 52:7–13

  25. 25.

    Plooy ACM, Dijk van M, Lohman PHM (1984) Induction and repair of DNA cross-links in Chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity. Cancer Res 44:2043–2051

  26. 26.

    Plooy ACM, Dijk M van, Berends F, Lohman PHM (1985) Formation and repair of DNA interstrand cross-links in relation to cytotoxicity and unscheduled DNA synthesis induced in control and mutant human cells treated with cis-diamminedichloroplatinum(II). Cancer Res 45:4178–4184

  27. 27.

    Prestayko AW, Bradner WT, Huftalen JB, Rose WC, Schurig JE, Cleare MJ, Hydes PC, Crooke ST (1979) Antileukemic (L1210) activity and toxicity of cis-dichlorodiammine platinum(II) analogs. Cancer Treat Rep 63:1503–1508

  28. 28.

    Roberts JJ, Fraval HNA (1980) Repair of cis-platinum(II) diamminedichloride-induced DNA damage and cell sensitivity. In: Prestayko AW, Crooke ST, Carter SK (eds) Cisplatin: Current status and new developments. Academic Press, New York, pp 57–77

  29. 29.

    Roberts JJ, Friedlos F (1982) The frequency of interstrand cross-links in DNA following reactions of cis-diammine dichloroplatinum(II) with cells in culture or DNA in vitro: stability of DNA cross-links and their repair. Chem-Biol Interact 39:181–189

  30. 30.

    Roberts JJ, Pascoe JM (1972) Cross-linking of complementary strands of DNA in mammalian cells by anti tumour platinum compounds. Nature 235:282–284

  31. 31.

    Roberts JJ, Thomson AJ (1979) The mechanism of action of antitumor platinum compounds. Prog Nucleic Acid Res Mol Biol 22:71–133

  32. 32.

    Rose WC, Schurig E, Huftalen JB, Bradner WT (1982) antitumor activity and toxicity of cisplatin analogs. Cancer Treat Rep 66:135–146

  33. 33.

    Scanlon KJ, Safirstein RL, Thies H, Gross RB, Waxman S, Guttenplan JB (1983) Inhibition of amino acid transport by cis-diamminedichloroplatinum(II) derivatives in L1210 murine leukemia cells. Cancer Res 43:4211–4215

  34. 34.

    Simpkins H, Pearlman LF (1986) Interaction of two second generation platinum antitumor drugs with mouse thymocytes. Cancer Res 46:1433–1439

  35. 35.

    Smith IE, Harland SJ, Robinson BA, Evans BD, Goodhart LC, Calvert AH, Yarnold J, Glees JP, Baker J, Ford HT (1985) Carboplatin: A very active new platin analog in the treatment of small cell lung cancer. Cancer Treat Rep 69:43–46

  36. 36.

    Strandberg MC, Bresnick E, Eastman A (1982) The significance of DNA cross-linking to cis-diamminedichloroplatinum(II) induced cytotoxicity in sensitive and resistant lines of murine leukemia L1210 cells. Chem-Biol Interact 39:169–180

  37. 37.

    Teicher BA, Holden SA, Frei E (1986) Characterization of a cis-diamminedichloroplatinum(II) resistant human squamous carcinoma cell line. Proc Am Assoc Cancer Res 27:261

  38. 38.

    Tobe ML, Kohkar AR (1977) Structure, activity, reactivity and solubility relationships of platinum diammine complexes. J Clin Hematol Oncol 77:114–137

  39. 39.

    Wilkinson R, Cox PJ, Jones M, Harrap KR (1978) Selection of potential second generation platinum compounds. Biochimie 60:851–857

  40. 40.

    Wiltshaw E, Evans BD, Jones AC, Baker JW, Calvert AH (1983) JM8, successor to cisplatin in advanced ovarian carcinoma? Lancet 1:587

  41. 41.

    Zwelling LA, Anderson T, Kohn KW (1979) DNA-protein and DNA interstrand cross-linking by cis- and transplatinum (II) diammine-dichloride in L1210 cells and relation to cytotoxicity. Cancer Res 39:365–369

Download references

Author information

Correspondence to P. A. Steerenberg.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Steerenberg, P.A., Vendrik, C.P.J., de Jong, W.H. et al. Resistance and cross-resistance of the IgM immunocytoma in the LOU/M Wsl rat for cisplatin, carboplatin, and iproplatin. Cancer Chemother. Pharmacol. 22, 51–57 (1988). https://doi.org/10.1007/BF00254181

Download citation

Keywords

  • Tumor Cell
  • Platinum
  • Cell Population
  • Growth Retardation
  • Antitumor Activity